NICE Draft Guidance: Rejects Keytruda In Head & Neck Cancer, Xospata In AML
But Positive On Lynparza And Ibrance In Certain Settings
Executive Summary
A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.